PP2A: The wolf in sheep’s clothing?

Cancers

Volumn 7, Issue 2, 2015, Pages 648-669

  Kiely, Maeve ^a   Kiely, Patrick A ^a  

^a UNIVERSITY OF LIMERICK   (Ireland)

Author keywords

Cancer; Cellular signaling; Phosphatase; PP2A; Tumour suppressor

Indexed keywords

ANTINEOPLASTIC AGENT; CANTHARIDIN; CISPLATIN; LB 100; LB 102; LENALIDOMIDE; NORCANTHARIDIN; OKADAIC ACID; PHOSPHOPROTEIN PHOSPHATASE 2A; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CARCINOGENESIS; DISEASE ASSOCIATION; DRUG EFFICACY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME STRUCTURE; GENE DELETION; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HUMAN; NONHUMAN; POINT MUTATION; PROTEIN ASSEMBLY; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION;

EID: 84929414337     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers7020648     Document Type: Review

References (145)

1. Hunter, T. Protein kinases and phosphatases: The yin and yang of protein phosphorylation and signaling. Cell 1995, 80, 225-236.
2. Pawson, T.; Scott, J.D. Signaling through scaffold, anchoring, and adaptor proteins. Science 1997, 278, 2075-2080.
3. Eichhorn, P.J.A.; Creyghton, M.P.; Bernards, R. Protein phosphatase 2A regulatory subunits and cancer. Biochim. Biophys. Acta 2009, 1795, 1-15.
4. Tonks, N.K. Protein tyrosine phosphatases: From genes, to function, to disease. Nat. Rev. Mol. Cell Biol. 2006, 7, 833-846.
5. Östman, A.; Hellberg, C.; Böhmer, F.D. Protein-tyrosine phosphatases and cancer. Nat. Rev. Cancer 2006, 6, 307-320.
6. Gallego, M.; Virshup, D.M. Protein serine/threonine phosphatases: Life, death, and sleeping. Curr. Opin. Cell Biol. 2005, 17, 197-202.
7. Stebbing, J.; Lit, L.C.; Zhang, H.; Darrington, R.S.; Melaiu, O.; Rudraraju, B.; Giamas, G. The regulatory roles of phosphatases in cancer. Oncogene 2013, 33, 939-953.
8. Arroyo, J.D.; Hahn, W.C. Involvement of PP2A in viral and cellular transformation. Oncogene 2005, 24, 7746-7755.
9. Westermarck, J.; Hahn, W.C. Multiple pathways regulated by the tumor suppressor PP2A in transformation. Trends Mol. Med. 2008, 14, 152-160.
10. Janssens, V.; Goris, J. Protein phosphatase 2A: A highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling. Biochem. J. 2001, 353, 417-439.
11. Schönthal, A.H. Role of serine/threonine protein phosphatase 2A in cancer. Cancer Lett. 2001, 170, 1-13.
12. Seshacharyulu, P.; Pandey, P.; Datta, K.; Batra, S.K. Phosphatase: PP2A structural importance, regulation and its aberrant expression in cancer. Cancer Lett. 2013, 335, 9-18.
13. Perrotti, D.; Neviani, P. Protein phosphatase 2A: A target for anticancer therapy. Lancet Oncol. 2013, 14, e229-e238.
14. Hemmings, B.A.; Adams-Pearson, C.; Maurer, F.; Müller, P.; Goris, J.; Merlevede, W.; Hofsteenge, J.; Stone, S.R. Alpha- and beta- forms of the 65-kDa subunit of protein phosphatase 2A have a similar 39 amino acid repeating structure. Biochemistry 1990, 29, 3166-3173.
15. Chen, W.; Wang, Z.; Jiang, C.; Ding, Y. PP2A-Mediated Anticancer Therapy. Gastroenterol. Res. Pract. 2013, 2013, doi:10.1155/2013/675429.
16. Yang, J.; Phiel, C. Functions of B56-containing PP2As in major developmental and cancer signaling pathways. Life Sci. 2010, 87, 659-666.
17. Zhou, J.; Pham, H.T.; Ruediger, R.; Walter, G. Characterization of the Aalpha and Abeta subunit isoforms of protein phosphatase 2A: Differences in expression, subunit interaction, and evolution. Biochem. J. 2003, 369, 387-398.
18. Bosch, M.; Cayla, X.; van Hoof, C.; Hemmings, B.A.; Ozon, R.; Merlevede, W.; Goris, J. The PR55 and PR65 subunits of protein phosphatase 2A from Xenopus laevis. Eur. J. Biochem. 1995, 230, 1037-1045.
19. Hendrix, P.; Turowski, P.; Mayer-Jaekel, R.E.; Goris, J.; Hofsteenge, J.; Merlevede, W.; Hemmings, B.A. Analysis of subunit isoforms in protein phosphatase 2A holoenzymes from rabbit and Xenopus. J. Biol. Chem. 1993, 268, 7330-7337.
20. Stone, S.R.; Hofsteenge, J.; Hemmings, B.A. Molecular cloning of cDNAs encoding two isoforms of the catalytic subunit of protein phosphatase 2A. Biochemistry 1987, 26, 7215-7220.
21. Khew-Goodall,Y.; Mayer, R.E.; Maurer, F.; Stone, S.R.; Hemmings, B.A. Structure and transcriptional regulation of protein phosphatase 2A catalytic subunit genes. Biochemistry 1991, 30, 89-97.
22. Xu, Y.; Xing, Y.; Chen, Y.; Chao, Y.; Lin, Z.; Fan, E.; Yu, J.W.; Strack, S.; Jeffrey, P.D.; Shi Y. Structure of the protein phosphatase 2A holoenzyme. Cell 2006, 127, 1239-1251.
23. Janssens, V.; Longin, S.; Goris, J. PP2A holoenzyme assembly: In cauda venenum (the sting is in the tail). Trends Biochem. Sci. 2008, 33, 113-121.
24. Xu, Y.; Chen, Y.; Zhang, P.; Jeffrey, P.D.; Shi, Y. Structure of a protein phosphatase 2A holoenzyme: Insights into B55-mediated Tau dephosphorylation. Mol. Cell 2008, 31, 873-885.
25. Sents, W.; Ivanova, E.; Lambrecht, C.; Haesen, D.; Janssens, V. The biogenesis of active protein phosphatase 2A holoenzymes: A tightly regulated process creating phosphatase specificity. FEBS J. 2013, 280, 644-661.
26. Janssens, V.; Goris, J.; van Hoof, C. PP2A: The expected tumor suppressor. Curr. Opin. Genet. Dev. 2005, 15, 34-41.
27. Kurimchak, A.; Graña, X. PP2A holoenzymes negatively and positively regulate cell cycle progression by dephosphorylating pocket proteins and multiple CDK substrates. Gene 2012, 499, 1-7.
28. Kitajima, T.S.; Sakuno, T.; Ishiguro, K.; Lemura, S.; Natsume, T.; Kawashima, S.A.; Watanabe, Y. Shugoshin collaborates with protein phosphatase 2A to protect cohesin. Nature 2006, 441, 46-52.
29. Tanno, Y.; Kitajima, T.S.; Honda, T.; Ando, Y.; Ishiguro, K.; Watanabe, Y. Phosphorylation of mammalian Sgo2 by Aurora B recruits PP2A and MCAK to centromeres. Genes Dev. 2010, 24, 2169-2179.
30. Strack, S.; Chang, D.; Zaucha, J.A.; Colbran, R.J.; Wadzinski, B.E. Cloning and characterization of Bδ, a novel regulatory subunit of protein phosphatase 2A. FEBS Lett. 1999, 460, 462-466.
31. Adams, D.G.; Coffee, R.L., Jr.; Zhang, H.; Pelech, S.; Strack, S.; Wadzinski, B.E. Positive regulation of Raf1-MEK1/2-ERK1/2 signaling by protein serine/threonine phosphatase 2A holoenzymes. J. Biol. Chem. 2005, 280, 42644-42654.
32. Ory, S.; Zhou, M.; Conrads, T.P.; Veenstra, T.D.; Morrison, D.K. Protein phosphatase 2A positively regulates Ras signaling by dephosphorylating KSR1 and Raf-1 on critical 14-3-3 binding sites. Curr. Biol. 2003, 13, 1356-1364.
33. Kurimchak, A.; Graña, X. PP2A Counterbalances Phosphorylation of pRB and Mitotic Proteins by Multiple CDKs Potential Implications for PP2A Disruption in Cancer. Genes Cancer 2012, 3, 739-748.
34. Ruediger, R.; Pham, H.T.; Walter, G. Alterations in protein phosphatase 2A subunit interaction in human carcinomas of the lung and colon with mutations in the Aβ subunit gene. Oncogene 2001, 20, 1892-1899.
35. Ruediger, R.; Pham, H.T.; Walter, G. Disruption of protein phosphatase 2A subunit interaction in human cancers with mutations in the Aα subunit gene. Oncogene 2001, 20, 10-15.
36. Sablina, A.A.; Chen, W.; Arroyo, J.D.; Corral, L.; Hector, M.; Bulmer, S.E.; DeCaprio, J.A.; Hahn, W.C. The tumor suppressor PP2A Aβ regulates the RalA GTPase. Cell 2007, 129, 969-982.
37. McConechy, M.K.; Anglesio, M.S.; Kalloger, S.E.; Yang, W.; Senz, J.; Chow, C.; Heravi-Moussavi, A.; Morin, G.B.; Mes-Masson, A.M.; Australian Ovarian Cancer Study Group; et al. Subtype-specific mutation of PPP2R1A in endometrial and ovarian carcinomas. J. Pathol. 2011, 223, 567-573.
38. Shih, I.-M.; Panuganti, P.K.; Kuo, K.T.; Mao, T.L.; Kuhn, E.; Jones, S.; Velculescu, V.E.; Kurman, R.J.; Wang, T.L. Somatic mutations of PPP2R1A in ovarian and uterine carcinomas. Am. J. Pathol. 2011, 178, 1442-1447.
39. Calin, G.A.; di Iasio, M.G.; Caprini, E.; Vorechovsky, I.; Natali, P.G.; Sozzi, G.; Croce, C.M.; Barbanti-Brodano, G.; Russo, G.; Negrini, M. Low frequency of alterations of the α (PPP2R1A) and β (PPP2R1B) isoforms of the subunit A of the serine-threonine phosphatase 2A in human neoplasms. Oncogene 2000, 19, 1191-1195.
40. Ruediger, R.; Ruiz, J.; Walter, G. Human cancer-associated mutations in the Aα subunit of protein phosphatase 2A increase lung cancer incidence in Aα knock-in and knockout mice. Mol. Cell. Biol. 2011, 31, 3832-3844.
41. Baysal, B.E.; Farr, J.E.; Goss, J.R.; Devlin, B.; Richard, C.W., III. Genomic organization and precise physical location of protein phosphatase 2A regulatory subunit A beta isoform gene on chromosome band 11q23. Gene 1998, 217, 107-116.
42. Wang, S.S.; Esplin, E.D.; Li, J.L.; Huang, L.; Gazdar, A.; Minna, J.; Evans, G.A. Alterations of the PPP2R1B gene in human lung and colon cancer. Science 1998, 282, 284-287.
43. Takagi, Y.; Futamura, M.; Yamaguchi, K.; Aoki, S.; Takahashi, T.; Saji, S. Alterations of the PPP2R1B gene located at 11q23 in human colorectal cancers. Gut 2000, 47, 268-271.
44. Chou, H.-C.; Chen, C.H.; Lee, H.S.; Lee, C.Z.; Huang, G.T.; Yang, P.M.; Lee, P.H.; Sheu, J.C. Alterations of tumour suppressor gene PPP2R1B in hepatocellular carcinoma. Cancer Lett. 2007, 253, 138-143.
45. Curtis, C.; Shah, S.P.; Chin, S.F.; Turashvili, G.; Rueda, O.M.; Dunning, M.J.; Speed, D.; Lynch, A.G.; Samarajiwa, S.; Yuan, Y.; et al. The genomic and transcriptomic architecture of 2000 breast tumours reveals novel subgroups. Nature 2012, 486, 346-352.
46. Cheng, Y.; Liu, W.; Kim, S.T.; Sun, J.; Lu, L.; Sun, J.; Zheng, S.L.; Isaacs, W.B.; Xu, J. Evaluation of PPP2R2A as a prostate cancer susceptibility gene: A comprehensive germline and somatic study. Cancer Genet. 2011, 204, 375-381.
47. The Cancer Genome Atlas Reaserch Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011, 474, 609-615.
48. Ruvolo, P.P.; Qui, Y.H.; Coombes, K.R.; Zhang, N.; Ruvolo, V.R.; Borthakur, G.; Konopleva, M.; Andreeff, M.; Kornblau, S.M. Low expression of PP2A regulatory subunit B55α is associated with T308 phosphorylation of AKT and shorter complete remission duration in acute myeloid leukemia patients. Leukemia 2011, 25, 1711-1717.
49. Tan, J.; Lee, P.L.; Li, Z.; Jiang, X.; Lim, Y.C.; Hooi, S.C.; Yu, Q. B55β-associated PP2A complex controls PDK1-directed myc signaling and modulates rapamycin sensitivity in colorectal cancer. Cancer Cell 2010, 18, 459-471.
50. Muggerud, A.A.; Rønneberg, J.A.; Wärnberg, F.; Botling, J.; Busato, F.; Jovanovic, J.; Solvang, H.; Bukholm, I.; Børresen-Dale, A.L.; Kristensen, V.N.; et al. Frequent aberrant DNA methylation of ABCB1, FOXC1, PPP2R2B and PTEN in ductal carcinoma in situ and early invasive breast cancer. Breast Cancer Res. 2009, 12, R3-R3.
51. Bialojan, C.; Takai, A. Inhibitory effect of a marine-sponge toxin, okadaic acid, on protein phosphatases. Specificity and kinetics. Biochem. J. 1988, 256, 283-290.
52. Marc, M. PP2A: Unveiling a reluctant tumor suppressor. Cell 2007, 130, 21-24.
53. Guergnon, J.; Godet, A.N.; Galioot, A.; Falanga, P.B.; Colle, J.H.; Cayla, X.; Garcia, A. PP2A targeting by viral proteins: A widespread biological strategy from DNA/RNA tumor viruses to HIV-1. Biochim. Biophys. Acta 2011, 1812, 1498-1507.
54. Zhao, R.Y.; Elder, R.T. Viral infections and cell cycle G2/M regulation. Cell Res. 2005, 15, 143-149.
55. Walter, G.; Ruediger, R.; Slaughter, C.; Mumby, M. Association of protein phosphatase 2A with polyoma virus medium tumor antigen. Proc. Natl. Acad. Sci. USA 1990, 87, 2521-2525.
56. Pallas, D.C.; Shahrik, L.K.; Martin, B.L.; Jaspers, S.; Miller, T.B.; Brautigan, D.L.; Roberts, T.M. Polyoma small and middle T antigens and SV40 small t antigen form stable complexes with protein phosphatase 2A. Cell 1990, 60, 167-176.
57. Campbell, K.S.; Auger, K.R.; Hemmings, B.A.; Roberts, T.M.; Pallas, D.C. Identification of regions in polyomavirus middle T and small T antigens important for association with protein phosphatase 2A. J. Virol. 1995, 69, 3721-3728.
58. Cristobal, I.; Manso, R.; Rincón, R.; Caramés, C.; Senin, C.; Borrero, A.; Martínez-Useros, J.; Rodriguez, M.; Zazo, S.; Aguilera, O.; et al. PP2A inhibition is a common event in colorectal cancer and its restoration using FTY720 shows promising therapeutic potential. Mol. Cancer Ther. 2014, 13, 938-947.
59. Letourneux, C.; Rocher, G.; Porteu, F. B56‐containing PP2A dephosphorylate ERK and their activity is controlled by the early gene IEX-1 and ERK. EMBO J. 2006, 25, 727-738.
60. Silverstein, A.M.; Barrow, C.A.; Davis, A.J.; Mumby, M.C. Actions of PP2A on the MAP kinase pathway and apoptosis are mediated by distinct regulatory subunits. Proc. Natl. Acad. Sci. USA 2002, 99, 4221-4226.
61. Rodriguez-Viciana, P.; Collins, C. Fried, M. Polyoma and SV40 proteins differentially regulate PP2A to activate distinct cellular signaling pathways involved in growth control. Proc. Natl. Acad. Sci. 2006, 103, 19290-19295.
62. Hahn, W.C.; Dessain, S.K.; Brooks, M.W.; King, J.E.; Elenbaas, B.; Sabatini, D.M.; de Caprio, J.A.; Weinberg, R.A. Enumeration of the simian virus 40 early region elements necessary for human cell transformation. Mol. Cell. Biol. 2002, 22, 2111-2123.
63. Yu, J.; Boyapati, A.; Rundell, K. Critical role for SV40 small-T antigen in human cell transformation. Virology 2001, 290, 192-198.
64. Marc, M. Regulation by tumour antigens defines a role for PP2A in signal transduction. Semin. Cancer Biol. 1995, 6, 229-237.
65. Chen, W.; Possemato, R.; Campbell, K.T.; Plattner, C.A.; Pallas, D.C.; Hahn, W.C. Identification of specific PP2A complexes involved in human cell transformation. Cancer Cell 2004, 5, 127-136.
66. Sontag, E.; Fedorov, S.; Kamibayashi, C.; Robbins, D.; Cobb, M.; Mumby, M. The interaction of SV40 small tumor antigen with protein phosphatase 2A stimulates the map kinase pathway and induces cell proliferation. Cell 1993, 75, 887-897.
67. Ugi, S.; Imamura, T.; Ricketts, W.; Olefsky, J.M. Protein phosphatase 2A forms a molecular complex with Shc and regulates Shc tyrosine phosphorylation and downstream mitogenic signaling. Mol. Cell. Biol. 2002, 22, 2375-2387.
68. Andrabi, S.; Gjoerup, O.V.; Kean, J.A.; Roberts, T.M.; Schaffhausen, B. Protein phosphatase 2A regulates life and death decisions via Akt in a context-dependent manner. Proc. Natl. Acad. Sci. USA 2007, 104, 19011-19016.
69. Eichhorn, P.J.; Creyghton, M.P.; Wilhelmsen, K.; van Dam, H.; Bernards, R. A RNA interference screen identifies the protein phosphatase 2A subunit PR55γ as a stress-sensitive inhibitor of c-SRC. PLoS Genet. 2007, 3, e218.
70. Stokoe, D.; McCormick, F. Activation of c-Raf-1 by ras and SRC through different mechanisms: Activation in vivo and in vitro. EMBO J. 1997, 16, 2384-2396.
71. Kuo, Y.-C.; Huang, K.Y.; Yang, C.H.; Yang, Y.S.; Lee, W.Y.; Chiang, C.W. Regulation of phosphorylation of Thr-308 of Akt, cell proliferation, and survival by the B55α regulatory subunit targeting of the protein phosphatase 2A holoenzyme to Akt. J. Biol. Chem. 2008, 283, 1882-1892.
72. Kiely, P.A.; O'Gorman, D.; Luong, K.; Ron, D.; O'Connor, R. Insulin-like growth factor I controls a mutually exclusive association of RACK1 with protein phosphatase 2A and β1 integrin to promote cell migration. Mol. Cell. Biol. 2006, 26, 4041-4051.
73. Suganuma, M.; Fujiki, H.; Suguri, H.; Yoshizawa, S.; Hirota, M.; Nakayasu, M.; Ojika, M.; Wakamatsu, K.; Yamada, K.; Sugimura, T. Okadaic acid: An additional non-phorbol-12-tetradecanoate-13-acetate-type tumor promoter. Proc. Natl. Acad. Sci. USA 1988, 85, 1768-1771.
74. Fujiki, H.; Suganuma, M. Tumor promotion by inhibitors of protein phosphatases 1 and 2A: The okadaic acid class of compounds. Adv. Cancer Res. 1993, 61, 143-143.
75. Lin, Y.-C.; Chen, K.C.; Chen, C.C.; Cheng, A.L.; Chen, K.F. CIP2A-mediated Akt activation plays a role in bortezomib-induced apoptosis in head and neck squamous cell carcinoma cells. Oral Oncol. 2012, 48, 585-593.
76. Junttila, M.R.; Puustinen, P.; Niemelä, M.; Ahola, R.; Arnold, H.; Böttzauw, T.; Ala-aho, R.; Nielsen, C.; Ivaska, J.; Taya, Y.; et al. CIP2A inhibits PP2A in human malignancies. Cell 2007, 130, 51-62.
77. Khanna, A.; Kauko, O.; Böckelman, C.; Laine, A.; Schreck, I.; Partanen, J.I.; Szwajda, A.; Bormann, S.; Bilgen, T.; Helenius, M.; et al. Chk1 targeting reactivates PP2A tumor suppressor activity in cancer cells. Cancer Res. 2013, 73, 6757-6769.
78. Cristóbal, I.; Garcia-Orti, L.; Cirauqui, C.; Cortes-Lavaud, X.; García-Sánchez, M.A.; Calasanz, M.J.; Odero, M.D. Overexpression of SET is a recurrent event associated with poor outcome and contributes to protein phosphatase 2A inhibition in acute myeloid leukemia. Haematologica 2012, 97, 543-550.
79. Kawada, M.; Amemiya, M.; Ishizuka, M.; Takeuchi, T. Cytostatin, an inhibitor of cell adhesion to extracellular matrix, selectively inhibits protein phosphatase 2A. Biochim. Biophys. Acta 1999, 1452, 209-217.
80. Wada, S.I.; Usami, I.; Umezawa, Y.; Inoue, H.; Ohba, S.; Someno, T.; Kawada, M.; Ikeda, D. Rubratoxin A specifically and potently inhibits protein phosphatase 2A and suppresses cancer metastasis. Cancer Sci. 2010, 101, 743-750.
81. Ugi, S.; Imamura, T.; Maegawa, H.; Egawa, K.; Yoshizaki, T.; Shi, K.; Obata, T.; Ebina, Y.; Kashiwagi, A.; Olefsky, J.M. Protein phosphatase 2A negatively regulates insulin's metabolic signaling pathway by inhibiting Akt (protein kinase B) activity in 3T3-L1 adipocytes. Mol. Cell. Biol. 2004, 24, 8778-8789.
82. Kiely, P.A.; Baillie, G.S.; Lynch, M.J.; Houslay, M.D.; O'Connor, R. Tyrosine 302 in RACK1 is essential for insulin-like growth factor-I-mediated competitive binding of PP2A and β1 integrin and for tumor cell proliferation and migration. J. Biol. Chem. 2008, 283, 22952-22961.
83. Yoshizaki, T.; Maegawa, H.; Egawa, K.; Ugi, S.; Nishio, Y.; Imamura, T.; Kobayashi, T.; Tamura, S.; Olefsky, J.M.; Kashiwagi, A. Protein phosphatase-2Cα as a positive regulator of insulin sensitivity through direct activation of phosphatidylinositol 3-kinase in 3T3-L1 adipocytes. J. Biol. Chem. 2004, 279, 22715-22726.
84. Khanna, A.; Okkeri, J.; Bilgen, T.; Tiirikka, T.; Vihinen, M.; Visakorpi, T.; Westermarck, J. ETS1 mediates MEK1/2-dependent overexpression of cancerous inhibitor of protein phosphatase 2A (CIP2A) in human cancer cells. PLoS ONE 2011, 6, e17979.
85. Padmanabhan, S.; Mukhopadhyay, A.; Narasimhan, S.D.; Tesz, G.; Czech, M.P.; Tissenbaum, H.A. A PP2A regulatory subunit regulates C. elegans insulin/IGF-1 signaling by modulating AKT-1 phosphorylation. Cell 2009, 136, 939-951.
86. Yang, Y.; Huang, Q.; Lu, Y.; Li, X.; Huang, S. Reactivating PP2A by FTY720 as a novel therapy for AML with C‐KIT tyrosine kinase domain mutation. J. Cell. Biochem. 2012, 113, 1314-1322.
87. Cristobal, I.; Garcia-Orti, L.; Cirauqui, C.; Alonso, M.M.; Calasanz, M.J.; Odero, M.D. PP2A impaired activity is a common event in acute myeloid leukemia and its activation by forskolin has a potent anti-leukemic effect. Leukemia 2011, 25, 606-614.
88. Dent, P. Ceramide in the prostate. Cancer Biol. Ther. 2013, 14, 881-882.
89. Kappos, L.; Radue, E.W.; O'Connor, P.; Polman, C.; Hohlfeld, R.; Calabresi, P.; Selmaj, K.; Agoropoulou, C.; Leyk, M.; Zhang-Auberson, L.; et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N. Engl. J. Med. 2010, 362, 387-401.
90. Khatri, B.; Barkhof, F.; Comi, G.; Hartung, H.P.; Kappos, L.; Montalban, X.; Pelletier, J.; Stites, T.; Wu, S.; Holdbrook, F.; et al. Comparison of fingolimod with interferon beta-1A in relapsing-remitting multiple sclerosis: A randomised extension of the TRANSFORMS study. Lancet Neurol. 2011, 10, 520-529.
91. O'Connor, P.; Comi, G.; Montalban, X.; Antel, J.; Radue, E.W.; de Vera, A.; Pohlmann, H.; Kappos, L.; FTY720 D2201 Study Group. Oral fingolimod (FTY720) in multiple sclerosis two-year results of a phase II extension study. Neurology 2009, 72, 73-79.
92. Cohen, J.A.; Barkhof, F.; Comi, G.; Hartung, H.P.; Khatri, B.O.; Montalban, X.; Pelletier, J.; Capra, R.; Gallo, P.; Izquierdo, G.; et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N. Engl. J. Med. 2010, 362, 402-415.
93. Brinkmann, V.; Billich, A.; Baumruker, T.; Heining, P.; Schmouder, R.; Francis, G.; Aradhye, S.; Burtin, P. Fingolimod (FTY720): Discovery and development of an oral drug to treat multiple sclerosis. Nat. Rev. Drug discov. 2010, 9, 883-897.
94. Matsuoka, Y.; Nagahara, Y.; Ikekita, M.; Shinomiya, T. A novel immunosuppressive agent FTY720 induced Akt dephosphorylation in leukemia cells. Br. J. Pharmacol. 2003, 138, 1303-1312.
95. Li, M.H.; Hla, T.; Ferrer, F. FTY720 inhibits tumor growth and enhances the tumor‐suppressive effect of topotecan in neuroblastoma by interfering with the sphingolipid signaling pathway. Pediatr. Blood Cancer 2013, 60, 1418-1423.
96. Azuma, H.; Takahara, S.; Horie, S.; Muto, S.; Otsuki, Y.; Katsuoka, Y. Induction of apoptosis in human bladder cancer cells in vitro and in vivo caused by FTY720 treatment. J. Urol. 2003, 169, 2372-2377.
97. Ubai, T.; Azuma, H.; Kotake, Y.; Inamoto, T.; Takahara, K.; Ito, Y.; Kiyama, S.; Sakamoto, T.; Horie, S.; Muto, S.; et al. FTY720 induced Bcl-associated and Fas-independent apoptosis in human renal cancer cells in vitro and significantly reduced in vivo tumor growth in mouse xenograft. Anticancer Res. 2007, 27, 75-88.
98. Marvaso, G.; Barone, A.; Amodio, N.; Raimondi, L.; Agosti, V.; Altomare, E.; Scotti, V.; Lombardi, A.; Bianco, R.; Bianco, C.; et al. Sphingosine analog fingolimod (FTY720) increases radiation sensitivity of human breast cancer cells in vitro. Cancer Biol. Ther. 2014, 15, 1.
99. Zhang, N.; Dai, L; Qi, Y.; Di, W.; Xia, P. Combination of FTY720 with cisplatin exhibits antagonistic effects in ovarian cancer cells: Role of autophagy. Int. J. Oncol. 2013, 42, 2053-2059.
100. Saddoughi, S.A.; Gencer, S.; Peterson, Y.K.; Ward, K.E.; Mukhopadhyay, A.; Oaks, J.; Bielawski, J.; Szulc, Z.M.; Thomas, R.J.; Selvam, S.P.; et al. Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A‐RIPK1‐dependent necroptosis. EMBO Mol. Med. 2013, 5, 105-121.
101. Baldacchino, S.; Saliba, C.; Petroni, V.; Fenech, A.G.; Borg, N.; Grech, G. Deregulation of the phosphatase, PP2A is a common event in breast cancer, predicting sensitivity to FTY720. EPMA J. 2014, 5, 3.
102. Roberts, K.G.; Smith, A.M.; McDougall, F.; Carpenter, H.; Horan, M.; Neviani, P.; Powell, J.A.; Thomas, D.; Guthridge, M.A.; Perrotti, D.; et al. Essential requirement for PP2A inhibition by the oncogenic receptor C-KIT suggests PP2A reactivation as a strategy to treat C-KIT+ cancers. Cancer Res. 2010, 70, 5438-5447.
103. Van Hoof, C.; Goris, J. Phosphatases in apoptosis: To be or not to be, PP2A is in the heart of the question. Biochim. Biophys. Acta 2003, 1640, 97-104.
104. Li, W.; Xie, L.; Chen, Z.; Zhu, Y.; Sun, Y.; Miao, Y.; Xu, Z.; Han, X. Cantharidin, a potent and selective PP2A inhibitor, induces an oxidative stress‐independent growth inhibition of pancreatic cancer cells through G2/M cell‐cycle arrest and apoptosis. Cancer Sci. 2010, 101, 1226-1233.
105. Schweyer, S.; Bachem, A.; Bremmer, F.; Steinfelder, H.J.; Soruri, A.; Wagner, W.; Pottek, T.; Thelen, P.; Hopker, W.W.; Radzun, H.J.; et al. Expression and function of protein phosphatase PP2A in malignant testicular germ cell tumours. J. Pathol. 2007, 213, 72-81.
106. Duong, F.H.; Dill, M.T.; Matter, M.S.; Makowska, Z.; Calabrese, D.; Dietsche, T.; Ketterer, S.; Terracciano, L.; Heim, M.H. Protein phosphatase 2A promotes hepatocellular carcinogenesis in the diethylnitrosamine mouse model through inhibition of p53. Carcinogenesis 2014, 35, 114-122.
107. Lu, J.; Kovach, J.S.; Johnson, F.; Chiang, J.; Hodes, R.; Lonser, R.; Zhuang, Z. Inhibition of serine/threonine phosphatase PP2A enhances cancer chemotherapy by blocking DNA damage induced defense mechanisms. Proc. Natl. Acad. Sci. USA 2009, 106, 11697-11702.
108. Boudreau, R.; Conrad, D.M.; Hoskin, D.W. Apoptosis induced by protein phosphatase 2A (PP2A) inhibition in T leukemia cells is negatively regulated by PP2A-associated p38 mitogen-activated protein kinase. Cell. Signal. 2007, 19, 139-151.
109. Santoro, M.F.; Annand, R.R.; Robertson, M.M.; Peng, Y.W.; Brady, M.J.; Mankovich, J.A.; Hackett, M.C.; Ghayur, T.; Walter, G.; Wong, W.W.; et al. Regulation of protein phosphatase 2A activity by caspase-3 during apoptosis. J. Biol. Chem. 1998, 273, 13119-13128.
110. Li, X.; Scuderi, A.; Letsou, A.; Virshup, D.M. B56-associated protein phosphatase 2A is required for survival and protects from apoptosis in Drosophila melanogaster. Mol. Cell. Biol. 2002, 22, 3674-3684.
111. MacKeigan, J.P.; Murphy, L.O.; Blenis, J. Sensitized RNAi screen of human kinases and phosphatases identifies new regulators of apoptosis and chemoresistance. Nat. Cell Biol. 2005, 7, 591-600.
112. Ruvolo, P.; Deng, X.; May, W. Phosphorylation of Bcl2 and regulation of apoptosis. Leukemia 2001, 15, 515-522.
113. Ruvolo, P.P.; Clark, W.; Mumby, M.; Gao, F.; May, W.S. A functional role for the B56 α-subunit of protein phosphatase 2A in ceramide-mediated regulation of Bcl2 phosphorylation status and function. J. Biol. Chem. 2002, 277, 22847-22852.
114. Simizu, S.; Tamura, Y.; Osada, H. Dephosphorylation of Bcl‐2 by protein phosphatase 2A results in apoptosis resistance. Cancer Sci. 2004, 95, 266-270.
115. Brown, C.J.; Lain, S.; Verma, C.S.; Fersht, A.R.; Lane, D.P. Awakening guardian angels: Drugging the p53 pathway. Nat. Rev. Cancer 2009, 9, 862-873.
116. Ajay, A.K.; Upadhyay, A.K.; Singh, S.; Vijayakumar, M.V.; Kumari, R.; Pandey, V.; Boppana, R.; Bhat, M.K. Cdk5 phosphorylates non-genotoxically overexpressed p53 following inhibition of PP2A to induce cell cycle arrest/apoptosis and inhibits tumor progression. Mol. Cancer 2010, 9, 204.
117. Li, D.W.; Liu, J.P.; Schmid, P.C.; Schlosser, R.; Feng. H.; Liu, W.B.; Yan, Q.; Gong, L.; Sun, S.M.; Deng, M.; et al. Protein serine/threonine phosphatase-1 dephosphorylates p53 at Ser-15 and Ser-37 to modulate its transcriptional and apoptotic activities. Oncogene 2006, 25, 3006-3022.
118. Crescenzi, E.; Raia, Z.; Pacifico, F.; Mellone, S.; Moscato, F.; Palumbo, G.; Leonardi, A. Down-regulation of wild-type p53-induced phosphatase 1 (Wip1) plays a critical role in regulating several p53-dependent functions in premature senescent tumor cells. J. Biol. Chem. 2013, 288, 16212-16224.
119. Shouse, G.P.; Cai, X.; Liu, X. Serine 15 phosphorylation of p53 directs its interaction with B56γ and the tumor suppressor activity of B56γ-specific protein phosphatase 2A. Mol. Cell. Biol. 2008, 28, 448-456.
120. Li, H.H.; Cai, X.; Shouse, G.P.; Piluso, L.G.; Liu, X. A specific PP2A regulatory subunit, B56γ, mediates DNA damage‐induced dephosphorylation of p53 at Thr55. EMBO J. 2007, 26, 402-411.
121. Nobumori, Y.; Liu, X. Characterization of tumor-derived B56γ mutations and their effect on the tumor suppressor function of B56γ-PP2A (802.21). FASEB J. 2014, 28, 802-821.
122. Duong, F.H.; Filipowicz, M.; Tripodi, M.; La Monica, N.; Heim, M.H. Hepatitis C virus inhibits interferon signaling through up-regulation of protein phosphatase 2A. Gastroenterology 2004, 126, 263-277.
123. Sallman, D.A.; Wei, S.; List, A. PP2A: The achilles heal in MDS with 5q deletion. Front. Oncol. 2014, 4, doi:10.3389/fonc.2014.00264.
124. Wei, S.; Chen, X.; Rocha, K.; Epling-Burnette, P.K.; Djeu, J.Y.; Liu, Q.; Byrd, J.; Sokol, L.; Lawrence, N.; Pireddu, R.; et al. A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide. Proc. Natl. Acad. Sci. USA 2009, 106, 12974-12979.
125. List, A.F.; Bennett, J.M.; Sekeres, M.A.; Skikne, B.; Fu, T.; Shammo, J.M.; Nimer, S.D.; Knight, R.D.; Giagounidis, A.; MDS-003 Study Investigators. Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del (5q) MDS. Leukemia 2014, 28, 1033-1040.
126. Honkanen, R.E. Cantharidin, another natural toxin that inhibits the activity of serine/threonine protein phosphatases types 1 and 2A. FEBS Lett. 1993, 330, 283-286.
127. Riordan, F.A.; Foroni, L.; Hoffbrand, A.V.; Mehta, A.B.; Wickremasinghe, R.G. Okadaic acid-induced apoptosis of HL60 leukemia cells is preceded by destabilization of Bcl-2 mRNA and downregulation of Bcl-2 protein. FEBS Lett. 1998, 435, 195-198.
128. Bonness, K.; Aragon, I.V.; Rutland, B.; Ofori-Acquah, S.; Dean, N.M.; Honkanen, R.E. Cantharidin-induced mitotic arrest is associated with the formation of aberrant mitotic spindles and lagging chromosomes resulting, in part, from the suppression of PP2Aα. Mol. Cancer Ther. 2006, 5, 2727-2736.
129. Huang, Y.; Liu, Q.; Liu, K.; Yagasaki, K.; Zhang, G. Suppression of growth of highly-metastatic human breast cancer cells by norcantharidin and its mechanisms of action. Cytotechnology 2009, 59, 201-208.
130. Liu, S.; Yu, H.; Kumar, S.M.; Martin, J.S.; Bing, Z.; Sheng, W.; Bosenberg, M.; Xu, X. Norcantharidin induces melanoma cell apoptosis through activation of TR3 dependent pathway. Cancer Biol. Ther. 2011, 12, 1005.
131. Kok, S.; Hong, C.Y.; Kuo, M.Y.; Lee, C.H.; Lee, J.J.; Lou, I.U.; Lee, M.S.; Hsiao, M.; Lin, S.K. Comparisons of norcantharidin cytotoxic effects on oral cancer cells and normal buccal keratinocytes. Oral Oncol. 2003, 39, 19-26.
132. Fan, Y.-Z.; Fu, J.Y.; Zhao, Z.M.; Chen, C.Q. Inhibitory effect of norcantharidin on the growth of human gallbladder carcinoma GBC-SD cells in vitro. Hepatobiliary Pancreat Dis. Int. 2007, 6, 72-80.
133. To, K.K.; Ho, Y.-P.; Au-Yeung, S.C. In vitro and in vivo suppression of growth of hepatocellular carcinoma cells by novel traditional Chinese medicine-platinum anti-cancer agents. Anticancer Drugs 2005, 16, 825-835.
134. Aird, K.M.; Ghanayem, R.B.; Peplinski, S.; Lyerly, H.K.; Devi, G.R. X-linked inhibitor of apoptosis protein inhibits apoptosis in inflammatory breast cancer cells with acquired resistance to an ErbB1/2 tyrosine kinase inhibitor. Mol. Cancer Ther. 2010, 9, 1432-1442.
135. Chung, V.M.; Mansfield, A.S.; Kovach, J. A phase 1 study of a novel inhibitor of protein phosphatase 2A alone and with docetaxel. J. Clin. Oncol. 2014, 32, TS2636.
136. Lu, J.; Zhuang, Z.; Song, D.K.; Mehta, G.U.; Ikejiri, B.; Mushlin, H.; Park, D.M.; Lonser, R.R. The effect of a PP2A inhibitor on the nuclear receptor corepressor pathway in glioma: Laboratory investigation. J. Neurosurg. 2010, 113, 225-233.
137. Zimmerman, R.; Peng, D.J.; Lanz, H.; Zhang, Y.H.; Danen-Van Oorschot, A.; Qu, S.; Backendorf, C.; Noteborn, M. PP2A inactivation is a crucial step in triggering apoptin-induced tumor-selective cell killing. Cell Death Dis. 2012, 3, e291.
138. McDermott, M.S.; Browne, B.C.; Conlon, N.T.; O'Brien, N.A.; Slamon, D.J.; Henry, M.; Meleady, P.; Clynes, M.; Dowling, P.; Crown, J.; et al. PP2A inhibition overcomes acquired resistance to HER2 targeted therapy. Mol. Cancer 2014, 13, 157.
139. Geyer, C.E.; Forster, J.; Lindquist, D.; Chan, S.; Romieu, CG.; Pienkowski, T.; Jagiello-Gruszfeld, A.; Crown, J.; Chan, A.; Kaufman, B.; et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N. Engl. J. Med. 2006, 355, 2733-2743.
140. Liu, L.; Greger, J.; Shi, H.; Liu, Y.; Greshock, J.; Annan, R.; Halsey, W.; Sathe, G.M.; Martin, A.M.; Gilmer, T.M. Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: Activation of AXL. Cancer Res. 2009, 69, 6871-6878.
141. Rexer, B.N.; Ham, A.J.; Rinehart, C.; Hill, S.; Granja-Ingram Nde, M.; González-Angulo, A.M.; Mills, G.B.; Dave, B.; Chang, J.C.; Liebler, D.C.; et al. Phosphoproteomic mass spectrometry profiling links SRC family kinases to escape from HER2 tyrosine kinase inhibition. Oncogene 2011, 30, 4163-4174.
142. Xia, W.; Bacus, S.; Hegde, P.; Husain, I.; Strum, J.; Liu, L.; Paulazzo, G.; Lyass, L.; Trusk, P.; Hill, J.; et al. A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer. Proc. Natl. Acad. Sci. USA 2006, 103, 7795-7800.
143. Xia, W.; Bacus, S.; Husain, I.; Liu, L.; Zhao, S.; Liu, Z.; Moseley, M.A., III; Thompson, J.W.; Chen, F.L.; Koch, K.M.; et al. Resistance to ErbB2 tyrosine kinase inhibitors in breast cancer is mediated by calcium-dependent activation of RelA. Mol. Cancer Ther. 2010, 9, 292-299.
144. Jegg, A.-M.; Ward, T.M.; Iorns, E.; Hoe, N.; Zhou, J.; Liu, X.; Singh, S.; Landgraf, R.; Pegram, M.D. PI3K independent activation of mTORC1 as a target in lapatinib-resistant ERBB2+ breast cancer cells. Breast Cancer Res. Treat. 2012, 136, 683-692.
145. Li, W.; Chen, Z.; Zong, Y.; Gong, F.; Zhu, Y.; Zhu, Y.; Lv, J.; Zhang, J.; Xie, L.; Sun, Y.; et al. PP2A inhibitors induce apoptosis in pancreatic cancer cell line PANC-1 through persistent phosphorylation of IKKα and sustained activation of the NF-κB pathway. Cancer Lett. 2011, 304, 117-127.